Figure 1
From: Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease
Overall study design: core and extension studies. *Not included in these analyses. †Not suspected to be related to study drug. AE, Adverse event; N, number of patients in treatment group; n, Number of patients with a measurement; SAE, Serious adverse event.